The notable results shown by newer glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) and emerging dual agonists, especially while managing cardio‐metabolic burdens, in T2D have encouraged fervent anecdotal and non‐anecdotal research also in T1D, indicating that non‐insulin injective agents can be effective and safe. The gene discussed is INS; the disease is type 2 diabetes mellitus.